Back to Results
First PageMeta Content
Eli Lilly and Company / Nitroimidazoles / Organobromides / TH-302 / Gemcitabine / Doxorubicin / Bortezomib / Docetaxel / Sunitinib / Chemistry / Organic chemistry / Organofluorides


ODAC Pediatric Subcommittee Development of TH-302 in Pediatric Oncology December 4, 2012 Threshold Pharmaceuticals, Inc.
Add to Reading List

Open Document

File Size: 414,39 KB

Share Result on Facebook

Company

EMD Serono Inc. / Threshold Pharmaceuticals Inc. / IND EOP2 STS SPA / Threshold Pharmaceuticals / /

Event

FDA Phase / /

MedicalCondition

melanoma / SCLC / febrile neutropenia / Cancer / Multiple Myeloma / gemcitabine EMR200592001 Pancreatic Cancer / pazopanib IST Hepatocellular carcinoma / Prevalent Feature Blood Vessels Hypoxic region Necrosis / Advanced leukemias / bortezomib IST Astrocytoma / Ph2 Ph3 Soft Tissue Sarcoma / Soft Tissue Sarcoma / Solid tumors / Thrombocytopenia / Pancreatic Cancer / mg/m2 Neutropenia / /

Organization

Inc. Pediatric Subcommittee / /

Person

Tillman Pearce / Antonio Gualberto / Robert Simon / /

Position

Director / EMD Serono / Medical Director / SVP Regulatory Affairs / Senior Medical Director / /

Product

TH-302 / /

SocialTag